Literature DB >> 10570435

Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma.

P A Gehrig1, L Van Le, B Olatidoye, J Geradts.   

Abstract

BACKGROUND: The aim of this study was to compare the concordance between immunohistochemical (IHC) and biochemical (RIA) methods for determining hormone receptor status in patients with endometrial carcinoma and to determine whether IHC expression of estrogen and progesterone receptors (ER and PR) has prognostic significance.
METHODS: Paraffin blocks were obtained from patients diagnosed with endometrial carcinoma between 1987 and 1991. IHC analysis for ER and PR expression was performed and scored based on staining intensity and the percentage of tumor cells with nuclear staining. Biochemical assays were performed on frozen tissues. Concordance between the two methods was evaluated and hormone receptor status was correlated with tumor grade, stage, recurrence and survival.
RESULTS: ER and PR expression, determined by IHC, correlated well with RIA levels (Spearmans correlation coefficient, P = 0.006 and 0.0005, respectively). Determination of ER and PR expression by both methods was correlated with tumor grade. Hazards ratios revealed that the absence of ER and PR expression, determined by both IHC and RIA, independently correlated with recurrence in early stage disease (P < 0.05).
CONCLUSIONS: Historically, receptors have been determined by RIA. In this study, IHC and RIA were equally suitable for determination of ER and PR. This is significant clinically as IHC has several advantages over RIA, including easier processing, lower cost, greater speed, and applicability to fixed tissue samples. In addition, ER negative status was predictive of the recurrence of Stage I tumors independent of tumor grade. ER status may aid the clinician in planning treatment when adjuvant treatment is controversial. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570435

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle
Journal:  Gynecol Oncol       Date:  2013-02-21       Impact factor: 5.482

2.  Expression of estrogen receptor-alpha and -beta in anterior vaginal walls of genuine stress incontinent women.

Authors:  X Fu; M Rezapour; X Wu; L Li; C Sjögren; U Ulmsten
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2003-08-02

Review 3.  Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.

Authors:  Yanli Zhang; Dong Zhao; Changguo Gong; Fengmei Zhang; Jing He; Wei Zhang; Yulan Zhao; Jing Sun
Journal:  World J Surg Oncol       Date:  2015-06-25       Impact factor: 2.754

4.  Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.

Authors:  Hila Kreizman-Shefer; Jana Pricop; Shlomit Goldman; Irit Elmalah; Eliezer Shalev
Journal:  Diagn Pathol       Date:  2014-03-31       Impact factor: 2.644

5.  Prognostic Value of 16α-18F-Fluoro-17β-Estradiol PET as a Predictor of Disease Outcome in Endometrial Cancer: A Prospective Study.

Authors:  Shizuka Yamada; Hideaki Tsuyoshi; Makoto Yamamoto; Tetsuya Tsujikawa; Yasushi Kiyono; Hidehiko Okazawa; Yoshio Yoshida
Journal:  J Nucl Med       Date:  2020-10-02       Impact factor: 10.057

6.  An exonuclease III protection-based electrochemical method for estrogen receptor assay.

Authors:  Sha Zhu; Ya Cao; Yuanyuan Xu; Yongmei Yin; Genxi Li
Journal:  Int J Mol Sci       Date:  2013-05-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.